Journal of Critical Care
Volume 23, Issue 1 , Pages 5-10, March 2008

The impact of ventilator-associated pneumonia on the Canadian health care system

  • John G. Muscedere, MD

      Affiliations

    • Queens University, Kingston, Canada K7L 2V7
  • ,
  • Claudio M. Martin, MD

      Affiliations

    • University of Western Ontario, Ontario, Canada N6A 4G5
  • ,
  • Daren K. Heyland, MD, MSc

      Affiliations

    • Queens University, Kingston, Canada K7L 2V7
    • Corresponding Author InformationCorresponding author. Tel.: +1 613 549 6666#3339; fax: +1 613 548 1351.

Abstract 

Introduction

Ventilator-associated pneumonia (VAP) is a cause of morbidity and mortality in critically ill patients. It is associated with increased health care costs and duration of mechanical ventilation. Using published data and information from public health care providers, we sought to determine the impact of VAP on the Canadian health care system.

Methods

Ventilator-associated pneumonia incidence, attributable mortality, and intensive care unit (ICU) utilization/resource data were obtained through Canadian published and institutional data. Ontario case cost methodology was used for the cost of a critical care bed which is CAN$2396 per day, excluding treatment costs. Antibiotic acquisition costs for Ontario were used. Physician reimbursement rates were obtained from the provincial ministries of health. Ventilator-associated pneumonia data, ICU resource data, and costs were combined to determine the impact of VAP.

Results

For the Canadian health care system; ICU utilization is 217 episodes per 100000 population and 1150 days of mechanical ventilation per 100000. The incidence of VAP is 10.6 cases per 1000 ventilator days (95% CI, 5.1-16.1). Ventilator-associated pneumonia increases ICU length of stay 4.3 days (95% CI, 1.5-7.0 days) per episode. The attributable mortality of VAP is 5.8% (95% CI, −2.4 to 14). The number of cases of VAP is estimated to be approximately 4000 cases per year (95% CI, 1900-6100). This results in 230 deaths per year with the lower and upper confidence intervals ranging from 0 to 580. Ventilator-associated pneumonia accounts for approximately 17000 ICU days per year or around 2% of all ICU days in Canada. The cost to the health care system is CAN$46 million (possible range, $10 million to 82 million) per year.

Conclusion

The impact of VAP on the Canadian health care system is considerable. Eradication of this preventable nosocomial infection would save lives and conserve scarce health care resources.

Keywords: Ventilator-associated pneumonia, Nosocomial infections, Canadian health care system

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflicts of interest: J Muscedere and D Heyland have received unrestricted research grants for studies in VAP unrelated to the present manuscript from Astra-Zeneca and Bayer Pharmaceuticals.

PII: S0883-9441(08)00004-X

doi:10.1016/j.jcrc.2007.11.012

Journal of Critical Care
Volume 23, Issue 1 , Pages 5-10, March 2008